Natural course of post-COVID symptoms in adults and children
© 2024. The Author(s)..
More than 200 million COVID-19 survivors have lasting symptoms after recovering, but the duration and related risk factors remain uncertain. This study focused on all 6551 patients diagnosed with COVID-19 at a medical institution in Hiroshima from March 2020 to July 2022. In November 2022, a questionnaire survey was conducted regarding post-COVID symptoms and their duration. The prevalence and duration of post-COVID symptoms were illustrated using the Kaplan-Meier method. Risk factors for symptoms lasting over 3 months and interfering with daily life were assessed via multivariate logistic regression. A total of 2421 survivors responded: 1391 adults, 1030 children, median age 34 years (IQR 9-55), 51·2% male, 36·7% hospitalized, median time from infection to the survey was 295 days (IQR 201-538). Upon their initial recovery, the prevalence of post-COVID symptoms was 78·4% in adults and 34·6% in children. Three months later, the rates were 47·6% and 10·8%. After over one year, they were 31·0% and 6·8%. Regarding symptoms interfere with daily life, 304 people (12.6%) experienced symptoms lasting for over three months, with independent risk factors including age, being female, diabetes mellitus, infection during the Delta period, and current smoking. There was no significant association between vaccination history and post-COVID symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Scientific reports - 14(2024), 1 vom: 16. Feb., Seite 3884 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sugiyama, Aya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 20.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-024-54397-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368559130 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368559130 | ||
| 003 | DE-627 | ||
| 005 | 20240220232308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-024-54397-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM368559130 | ||
| 035 | |a (NLM)38365846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sugiyama, Aya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Natural course of post-COVID symptoms in adults and children |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a More than 200 million COVID-19 survivors have lasting symptoms after recovering, but the duration and related risk factors remain uncertain. This study focused on all 6551 patients diagnosed with COVID-19 at a medical institution in Hiroshima from March 2020 to July 2022. In November 2022, a questionnaire survey was conducted regarding post-COVID symptoms and their duration. The prevalence and duration of post-COVID symptoms were illustrated using the Kaplan-Meier method. Risk factors for symptoms lasting over 3 months and interfering with daily life were assessed via multivariate logistic regression. A total of 2421 survivors responded: 1391 adults, 1030 children, median age 34 years (IQR 9-55), 51·2% male, 36·7% hospitalized, median time from infection to the survey was 295 days (IQR 201-538). Upon their initial recovery, the prevalence of post-COVID symptoms was 78·4% in adults and 34·6% in children. Three months later, the rates were 47·6% and 10·8%. After over one year, they were 31·0% and 6·8%. Regarding symptoms interfere with daily life, 304 people (12.6%) experienced symptoms lasting for over three months, with independent risk factors including age, being female, diabetes mellitus, infection during the Delta period, and current smoking. There was no significant association between vaccination history and post-COVID symptoms | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Takafuta, Toshiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Tomoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kitahara, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshinaga, Yayoi |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Kanon |e verfasserin |4 aut | |
| 700 | 1 | |a Chanroth, Chhoung |e verfasserin |4 aut | |
| 700 | 1 | |a Ataa, Akuffo Golda |e verfasserin |4 aut | |
| 700 | 1 | |a Phyo, Zayar |e verfasserin |4 aut | |
| 700 | 1 | |a Kurisu, Akemi |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Ko |e verfasserin |4 aut | |
| 700 | 1 | |a Akita, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kishita, Eisaku |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwabara, Masao |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Junko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 16. Feb., Seite 3884 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:16 |g month:02 |g pages:3884 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-024-54397-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 16 |c 02 |h 3884 | ||